Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1954 1
1955 1
1956 1
1957 1
1965 1
1968 1
1970 2
1971 1
1975 1
1984 2
1987 1
1989 1
1990 2
1992 1
1994 3
1998 1
1999 1
2001 1
2002 2
2003 2
2004 4
2005 15
2006 9
2007 11
2008 1
2010 2
2011 3
2012 2
2013 3
2014 6
2015 8
2016 10
2017 6
2018 7
2019 11
2020 16
2021 6
2022 8
2023 10
2024 15

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

155 results

Results by year

Filters applied: . Clear all
Page 1
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Hauser SL, et al. Among authors: tomic d. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. N Engl J Med. 2020. PMID: 32757523 Clinical Trial.
Dysphagia: Thinking outside the box.
Philpott H, Garg M, Tomic D, Balasubramanian S, Sweis R. Philpott H, et al. Among authors: tomic d. World J Gastroenterol. 2017 Oct 14;23(38):6942-6951. doi: 10.3748/wjg.v23.i38.6942. World J Gastroenterol. 2017. PMID: 29097867 Free PMC article. Review.
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D; evolutionRMS investigators. Montalban X, et al. Among authors: tomic d. Lancet Neurol. 2024 Nov;23(11):1119-1132. doi: 10.1016/S1474-4422(24)00328-4. Epub 2024 Sep 19. Lancet Neurol. 2024. PMID: 39307151 Clinical Trial.
Optimizing treatment success in multiple sclerosis.
Ziemssen T, Derfuss T, de Stefano N, Giovannoni G, Palavra F, Tomic D, Vollmer T, Schippling S. Ziemssen T, et al. Among authors: tomic d. J Neurol. 2016 Jun;263(6):1053-65. doi: 10.1007/s00415-015-7986-y. Epub 2015 Dec 24. J Neurol. 2016. PMID: 26705122 Free PMC article. Review.
Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis.
Montalban X, Wallace D, Genovese MC, Tomic D, Parsons-Rich D, Le Bolay C, Kao AH, Guehring H. Montalban X, et al. Among authors: tomic d. J Neurol Neurosurg Psychiatry. 2023 Jan;94(1):1-9. doi: 10.1136/jnnp-2022-328799. Epub 2022 Nov 23. J Neurol Neurosurg Psychiatry. 2023. PMID: 36418156 Free PMC article. Clinical Trial.
Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS.
Kappos L, Radue EW, Comi G, Montalban X, Butzkueven H, Wiendl H, Giovannoni G, Hartung HP, Derfuss T, Naegelin Y, Sprenger T, Mueller-Lenke N, Griffiths S, von Rosenstiel P, Gottschalk R, Zhang Y, Dahlke F, Tomic D; TOFINGO study group. Kappos L, et al. Among authors: tomic d. Neurology. 2015 Jul 7;85(1):29-39. doi: 10.1212/WNL.0000000000001706. Epub 2015 May 29. Neurology. 2015. PMID: 26024899 Free PMC article.
Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study.
Montalban X, Piasecka-Stryczynska K, Kuhle J, Benkert P, Arnold DL, Weber MS, Seitzinger A, Guehring H, Shaw J, Tomic D, Hyvert Y, Harlow DE, Dyroff M, Wolinsky JS. Montalban X, et al. Among authors: tomic d. Mult Scler. 2024 Apr;30(4-5):558-570. doi: 10.1177/13524585241234783. Epub 2024 Mar 4. Mult Scler. 2024. PMID: 38436271 Free PMC article. Clinical Trial.
[Infection in hernia surgery].
Zuvela M, Milićević M, Galun D, Lekić N, Basarić D, Tomić D, Petrović M, Palibrk I. Zuvela M, et al. Among authors: tomic d. Acta Chir Iugosl. 2005;52(1):9-26. doi: 10.2298/aci0501009z. Acta Chir Iugosl. 2005. PMID: 16119310 Review. Serbian.
155 results